Skip to content
PARTICIPER À UNE ÉTUDELISTE DE DIFFUSION
X page opens in new window
AB SCIENCE
Discipline serving the patients
AB SCIENCE
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in sickle cell disease
    • Masitinib in neurodegenerative disorders
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Sickle Cell Disease
      • Alzheimer’s Disease
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Articles of Incorporation
      • Board of Directors Charter
      • Information document
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact
  • FR
  • EN
Search:
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in sickle cell disease
    • Masitinib in neurodegenerative disorders
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Sickle Cell Disease
      • Alzheimer’s Disease
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Articles of Incorporation
      • Board of Directors Charter
      • Information document
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact

Tag Archives: 2019

You are here:
  1. Home
  2. Entries tagged with "2019"

Summary of the webconference held on June 4, 2019

2019By Alexis BERNARD4 June 2019

04/06/2019 – AB Science is providing a summary of the web conference held on 4 June, 2019

June 4 2019 web conference presentation

2019By Alexis BERNARD4 June 2019

04/06/2019 – AB Science web conference presentation (Part 1)

Web conference on June 4 and 5, 2019

2019By Alexis BERNARD30 May 2019

30/05/2019 – AB Science will hold a web conference on its outlook for 2019 on June 4 and 5, 2019 from 5.30 pm to 7pm CET

Lifting of the ANSM clinical hold

2019By Alexis BERNARD28 May 2019

28/05/2019 – AB Science announces the lifting of the ANSM clinical hold.

Webconference presentation on masitinib + isoquercetin in COVID-19

2020By Alexis BERNARD11 May 2019

11/05/2019 – Webconference presentation on masitinib + isoquercetin in COVID-19

Annual financial results as of 31 December, 2018

2019By Alexis BERNARD30 April 2019

30/04/2019 – AB Science reports its annual financial results as of 31 December 2018.

Presentation of new masitinib preclinical data in ALS at the 2019 Muscular Dystrophy Association Conference

2019By Alexis BERNARD16 April 2019

16/04/2019- AB Science presented new preclinical data for masitinib in ALS at the 2019 Muscular Dystrophy Association Conference.

Acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference

2019By Alexis BERNARD21 March 2019

21/03/2019 – AB Science announces acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference.

←12345←
© 2026 AB SCIENCE
Go to Top